Summit Therapeutics Inc. — Director's Dealing 2023

Dec 13, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Summit Therapeutics Inc. (SMMT)
CIK: 0001599298
Period of Report: 2023-12-11

Reporting Person: Zanganeh Mahkam (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-12-11	Common Stock	X	489814	$1.44	Acquired	489814	Direct
2023-12-12	Common Stock	P	5000	$2.07	Acquired	494814	Direct
2023-12-11	Common Stock	X	315681	$1.58	Acquired	24889479	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-12-11	Warrant (right to buy)	$1.44	X	489814	Disposed	2025-06-30	Common Stock (489814)	Direct
2023-12-11	Warrant (right to buy)	$1.58	X	315681	Disposed	2029-12-24	Common Stock (315681)	Indirect

Footnotes

F1: The Reporting Person exercised certain warrants to purchase shares of common stock in accordance with the terms of such warrants.

F2: The Reporting Person purchased these shares in a single transaction on the open market.

F3: The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.